Comprehensive Genomic Analysis in Tissue Samples from Patients with Recurrent or Stage IV Non-small Cell Lung Cancer

Inclusion Criteria

• Stage IV or recurrent non-small cell lung cancer
• Patients who have archival tissue for genomic analysis, are willing and able to undergo a new biopsy to obtain tumor tissue for genomic analysis, or whose tumor has already undergone genomic analysis
• Eastern Cooperative Oncology Group (ECOG) performance status 0-2
• Life expectancy >= 3 months
• Signed informed consent that details the investigational nature of the study according to institutional and federal guidelines

Exclusion Criteria

• Patients with concurrent malignancy; patients with prior or concurrent malignancy will be allowed as long as the treating physician considers it unlikely to impact the clinical outcome of the patient
• Serious medical illness that may affect the clinical outcome of the patient, as determined by the treating physician; serious medical illness includes but is not limited to: uncontrolled congestive heart failure, uncontrolled angina, myocardial infarction or cerebrovascular event with 6 months of registration, history of chronic active hepatitis or history of human immunodeficiency virus (HIV) or an active bacterial infection will not be eligible
• Pregnant or lactating women; female patients of child bearing potential will be informed that if they do enroll on a therapeutic trial, based on the genomic analyses, that they may not be able to enroll on a clinical trial if they are pregnant; all sexually active patients will be informed that patients enrolling on a therapeutic trial have to use contraceptive methods to prevent pregnancy